By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act … Read more
By Lisa Thompson NASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Tower (NASDAQ:TSEM) continued year-over-year revenue growth in Q4 2024 and expects that to continue sequentially and year-over-year throughout 2025. The growth will be back-half weighted as capacity comes online in Italy, Texas, and Japan. For the 2024 year, revenues and earnings were basically flat with … Read more
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization efforts and sales will be focused on recombinant serum albumin. Further down the road, additional proteins may be added including bovine albumin, bovine transferrin … Read more
But capping interest rates is not a cure-all for debt-driven woes. A 2018 World Bank study of interest rates on loans in other countries found that interest rate caps set below market rates reduced access to credit for low and middle-income borrowers. Banks take on risk by extending credit to consumers, and that risk increases … Read more
By Steven Ralston, CFA NYSE:UHAL READ THE FULL UHAL RESEARCH REPORT U-Haul Holding Company (NYSE:UHAL) reported financial results for 3Q FY2025 on February 5th. Total revenues increased 3.7% to approximately $1.39 billion, primarily due to stronger revenue growth of 4.6% in the self-moving equipment rental business, along with a 7.9% increase in theself-storage segment. In … Read more
